Clinical trial NCT00691743: Upper GI Symptoms In Patients Receiving Acetylsalicylic Acid/NSAIDs - NSAIDs Wave 2
Official title: Upper GI Symptoms In Patients Receiving Acetylsalicylic Acid/NSAIDs - NSAIDs Wave 2
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Upper-GI Symptoms
Keywords: Upper GI Symptoms
GERD
NSAIDs
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-06-05
Enrollment: 850
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care

Brief summary: The current epidemiological study will be undertaken in GP's and specialized private doctors. In total, 85 general practitioners, orthopedics, rheumatologists and cardiologist will take part in the study. Data will be collected for 850 patients who visit their physician for medical conditions that require the use of acetylsalicylic acid and/or NSAIDS. The first 10 consecutive patients who visit their GP/orthopedic/rheumatologist/cardiologists and are currently receiving acetylsalicylic acid and/or NSAIDS will be included in the study.


Eligibility criteria: Inclusion Criteria:

* Acetylsalicylic acid/NSAIDS intake for at least 5 days of a week during the past month before the patient's visit to the clinician

Exclusion Criteria:

* Patients who are not willing to sign of the Informed Consent Form

Primary outcomes:
measure: Frequency (%) of patients in the Greek Primary Practice, presenting Upper GI Symptoms while receiving NSAIDS treatment with/without gastroprotective measures.
timeFrame: Single visit / once
Secondary outcomes:
measure: The nature of upper GI symptoms (Dyspepsia and GERD) experienced by patients receiving acetylsalicylic acid and / or NSAIDS treatment
timeFrame: single visit / once
measure: To determine the main indications for acetylsalicylic acid and or NSAIDS prescription among GPs and specialized private doctors in Greece.
timeFrame: single visit / once
Other outcomes:
Locations:
city: Agrinio
country: Greece
facility: Research Site
city: Alexandroupoli
country: Greece
facility: Research Site
city: Argostoli
country: Greece
facility: Research Site
city: Athens
country: Greece
facility: Research Site
city: Chalkida
country: Greece
facility: Research Site
city: Drama
country: Greece
facility: Research Site
city: Heraklion
country: Greece
facility: Research Site
city: Ioannina
country: Greece
facility: Research Site
city: Kalamata
country: Greece
facility: Research Site
city: Kallikratia
country: Greece
facility: Research Site
city: Katerini
country: Greece
facility: Research Site
city: Kiato
country: Greece
facility: Research Site
city: Komotini
country: Greece
facility: Research Site
city: Korinthos
country: Greece
facility: Research Site
city: Kozani
country: Greece
facility: Research Site
city: Lamia
country: Greece
facility: Research Site
city: Larisa
country: Greece
facility: Research Site
city: Patra
country: Greece
facility: Research Site
city: Peireous
country: Greece
facility: Research Site
city: Pirgos
country: Greece
facility: Research Site
city: Preveza
country: Greece
facility: Research Site
city: Rethimnon
country: Greece
facility: Research Site
city: Serres
country: Greece
facility: Research Site
city: Thessaloniki
country: Greece
facility: Research Site
city: Tripoli
country: Greece
facility: Research Site
city: Volos
country: Greece
facility: Research Site
city: Xania
country: Greece
facility: Research Site
Study officials:
affiliation: Errikos Ntinan Hospital, Athens, Greece
name: Rokkas Theodoros, MD
role: PRINCIPAL_INVESTIGATOR
References: